Compare VTSI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | KLRS |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 44.5M |
| IPO Year | 1999 | 2020 |
| Metric | VTSI | KLRS |
|---|---|---|
| Price | $2.62 | $2.02 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $6.25 | ★ $17.67 |
| AVG Volume (30 Days) | 26.9K | ★ 70.5K |
| Earning Date | 11-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.70 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,971.00 | $165,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.40 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $1.78 |
| 52 Week High | $6.08 | $11.88 |
| Indicator | VTSI | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 42.00 | 36.04 |
| Support Level | $2.54 | N/A |
| Resistance Level | $2.82 | $4.37 |
| Average True Range (ATR) | 0.12 | 0.15 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 32.14 | 43.69 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.